MeiraGTx Holdings plc announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models. Under the terms of the agreement, MeiraGTx will receive a $200 million upfront cash payment upon the closing of the transaction, which is anticipated in the second calendar quarter of 2025.
The collaboration includes the formation of a new joint venture, Hologen Neuro AI Ltd, which will be funded with up to an additional $230 million in committed capital from Hologen. This funding is dedicated to fully financing the development of AAV-GAD for Parkinson’s disease through commercialization, as well as supporting earlier-stage CNS clinical programs, including AAV-BDNF for genetic obesity.
MeiraGTx will retain a 30% ownership stake in the Hologen Neuro AI Ltd joint venture and will lead all clinical development and manufacturing. The company will also enter into exclusive clinical and commercial manufacturing supply agreements with the joint venture. Additionally, Hologen will acquire a minority stake in MeiraGTx’s manufacturing subsidiary and contribute to its annual funding, leveraging Hologen’s AI capabilities to optimize MeiraGTx’s proprietary manufacturing processes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.